Evidence map›Paper›PMID 37429022›Full record

ArticleJAMA otolaryngology-- head & neck surgery2023

A New Personalized Oral Cancer Survival Calculator to Estimate Risk of Death From Both Oral Cancer and Other Causes.

Louise Davies, Benjamin F Hankey, Zhuoqiao Wang, Zhaohui Zou, Susan Scott, Minjung Lee, Hyunsoon Cho, Eric J Feuer

Abstract read
In one paragraph

Article in JAMA otolaryngology-- head & neck surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Louise DaviesVA Outcomes Group, Department of Veterans Affairs Medical Center, White River Junction, Vermont.
Benjamin F HankeyStatistical Research and Application Branch, Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.
Zhuoqiao WangInformation Management Services, Calverton, Maryland.
Zhaohui ZouInformation Management Services, Calverton, Maryland.
Susan ScottSurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.
Minjung LeeDepartment of Statistics, Kangwon National University, Chuncheon, Gangwon, Korea.
Hyunsoon ChoDepartment of Cancer AI and Digital Health, National Cancer Center Graduate School of Cancer Science and Policy, and the Integrated Biostatistics Branch, Division of Cancer Data Science, National Cancer Center, Goyang, Gyeonggi-do, Korea.
Eric J FeuerStatistical Research and Application Branch, Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Standard cancer prognosis models typically do not include much specificity in characterizing competing illnesses or general health status when providing prognosis estimates, limiting their utility for individuals, who must consider their cancer in the context of their overall health. This is especially true for patients with oral cancer, who frequently have competing illnesses. Objective: To describe a statistical framework and accompanying new publicly available calculator that provides personalized estimates of the probability of a patient surviving or dying from cancer or other causes, using oral cancer as the first data set. Design, Setting, and Participants: The models used data from the Surveillance, Epidemiology, and End Results (SEER) 18 registry (2000 to 2011), SEER-Medicare linked files, and the National Health Interview Survey (NHIS) (1986 to 2009). Statistical methods developed to calculate natural life expectancy in the absence of the cancer, cancer-specific survival, and other-cause survival were applied to oral cancer data and internally validated with 10-fold cross-validation. Eligible participants were aged between 20 and 94 years with oral squamous cell carcinoma. Exposures: Histologically confirmed oral cancer, general health status, smoking, and selected serious comorbid conditions. Main Outcomes and Measures: Probabilities of surviving or dying from the cancer or from other causes, and life expectancy in the absence of the cancer. Results: A total of 22 392 patients with oral squamous cell carcinoma (13 544 male [60.5%]; 1476 Asian and Pacific Islander [6.7%]; 1792 Black [8.0%], 1589 Hispanic [7.2%], 17 300 White [78.1%]) and 402 626 NHIS interviewees were included in this calculator designed for public use for patients ages 20 to 86 years with newly diagnosed oral cancer to obtain estimates of health status-adjusted age, life expectancy in the absence of the cancer, and the probability of surviving, dying from the cancer, or dying from other causes within 1 to 10 years after diagnosis. The models in the calculator estimated that patients with oral cancer have a higher risk of death from other causes than their matched US population, and that this risk increases by stage. Conclusions and relevance: The models developed for the calculator demonstrate that survival estimates that exclude the effects of coexisting conditions can lead to underestimates or overestimates of survival. This new calculator approach will be broadly applicable for developing future prognostic models of cancer and noncancer aspects of a person's health in other cancers; as registries develop more linkages, available covariates will become broader, strengthening future tools.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsMouth NeoplasmsAdultAgedAged, 80 and overHumansMaleMedicareMiddle AgedSEER ProgramSquamous Cell Carcinoma of Head and NeckUnited StatesYoung Adult

Identifiers

PMID37429022
PMCPMC10334297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.